The use of novel oral anticoagulants (NOACs) has increased in recent times in an effort to overcome the shortcomings of warfarin. They are being used primarily for the prevention of thrombosis caused by atrial fibrillation and offer the advantages of having fewer drug interactions than warfarin, no dietary restrictions, and no requirement for regular blood tests. Although there is reportedly less postoperative bleeding even if the drug is not discontinued during procedures that can cause local bleeding, such as dental procedures, no well-designed clinical studies have assessed postoperative bleeding associated with the use of these drugs. This article reports a case of a 74-year-old male patient who was taking rivaroxaban. The patient under...
OBJECTIVES Bleeding after tooth extraction range from minor bleeding to life-threating haemorrhag...
Objective: The effect of direct oral anticoagulants (DOACs) on the risk of bleeding after tooth extr...
Several novel oral anticoagulant drugs (NOACs) have recently been approved for use in patients with ...
OBJECTIVE: Several novel oral anticoagulants (NOACs) are currently prescribed for patients suffering...
The management of patients under treatment with Direct Oral Anticoagulants (DOACs) has led clinician...
AbstractBackground/purposeThe nonvitamin K antagonist oral anticoagulants direct-thrombin inhibitor ...
The number of patients using direct oral anticoagulants (DOACs) instead of vitamin K antagonists (VK...
A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advan...
Background The aim of this paper is to contribute to the discussion on how to approach patients taki...
The risk of bleeding in the setting of anticoagulant therapy continues to be re-evaluated following ...
Patients on anticoagulant therapy for the prevention of cardiovascular accidents present an increase...
To establish whether there is a high enough risk of bleeding in patients who take oral anticoagulant...
Four novel direct oral anticoagulants (DOACs) named dabigatran, rivaroxaban, edoxaban and apixaban h...
Description: x, 77 leaves : ill. ; 30 cm. Notes: "October 1999". Thesis (M. D. S.)--University of Ot...
Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor...
OBJECTIVES Bleeding after tooth extraction range from minor bleeding to life-threating haemorrhag...
Objective: The effect of direct oral anticoagulants (DOACs) on the risk of bleeding after tooth extr...
Several novel oral anticoagulant drugs (NOACs) have recently been approved for use in patients with ...
OBJECTIVE: Several novel oral anticoagulants (NOACs) are currently prescribed for patients suffering...
The management of patients under treatment with Direct Oral Anticoagulants (DOACs) has led clinician...
AbstractBackground/purposeThe nonvitamin K antagonist oral anticoagulants direct-thrombin inhibitor ...
The number of patients using direct oral anticoagulants (DOACs) instead of vitamin K antagonists (VK...
A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advan...
Background The aim of this paper is to contribute to the discussion on how to approach patients taki...
The risk of bleeding in the setting of anticoagulant therapy continues to be re-evaluated following ...
Patients on anticoagulant therapy for the prevention of cardiovascular accidents present an increase...
To establish whether there is a high enough risk of bleeding in patients who take oral anticoagulant...
Four novel direct oral anticoagulants (DOACs) named dabigatran, rivaroxaban, edoxaban and apixaban h...
Description: x, 77 leaves : ill. ; 30 cm. Notes: "October 1999". Thesis (M. D. S.)--University of Ot...
Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor...
OBJECTIVES Bleeding after tooth extraction range from minor bleeding to life-threating haemorrhag...
Objective: The effect of direct oral anticoagulants (DOACs) on the risk of bleeding after tooth extr...
Several novel oral anticoagulant drugs (NOACs) have recently been approved for use in patients with ...